Equities Analysts Offer Predictions for TSE:BHC Q3 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research lifted their Q3 2026 earnings estimates for Bausch Health Companies in a research note issued to investors on Friday, July 24th. Zacks Research analyst Team now anticipates that the company will earn $1.47 per share for the quarter, up from their previous forecast of $1.42. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2027 earnings at $1.16 EPS, Q3 2027 earnings at $1.47 EPS, Q4 2027 earnings at $1.33 EPS, FY2027 earnings at $5.10 EPS, Q1 2028 earnings at $0.81 EPS, Q2 2028 earnings at $1.16 EPS and FY2028 earnings at $4.34 EPS.

Bausch Health Companies (TSE:BHC) last posted its quarterly earnings data on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. Bausch Health Companies had a negative net margin of 13.54% and a positive return on equity of 120.43%. The firm had revenue of C$3.51 billion during the quarter.

Separately, Jefferies Financial Group raised Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of “Hold”.

Bausch Health Companies Stock Up 1.4%

TSE:BHC opened at C$6.34 on Tuesday. The company has a market cap of C$2.37 billion, a price-to-earnings ratio of -1.96, a P/E/G ratio of 0.21 and a beta of 0.97. The company has a debt-to-equity ratio of -1,009.96, a quick ratio of 0.58 and a current ratio of 1.32. The stock’s fifty day moving average price is C$7.00 and its two-hundred day moving average price is C$7.63. Bausch Health Companies has a 52-week low of C$6.10 and a 52-week high of C$11.97.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.